Helpdesk

Sales contact

Home > Resources > Emerging Biopharma & Biotech (EBP) – 5 key success factors for your clinical trials

Emerging Biopharma & Biotech (EBP) – 5 key success factors for your clinical trials

Last updated: July 3, 2024

With so much at stake, consider partnering with an eCOA and DCT expert!

Kayentis offers a unified platform featuring trustworthy services to ensure the success of electronic Clinical Outcome Assessment (eCOA) and decentralized clinical trials (DCT):

18+ years’ eCOA experience navigating diverse clinical trial challenges

A unified platform for decentralized clinical trials enhancing patient and site experience

Trusted partnership ensuring top-quality service delivery

Clinical and scientific experts empowering and supporting your teams

Therapeutic expertise addressing the unique needs of specific populations

Subscribe to our newsletter

Expanding investor confidence: The strategic value of Patient Reported Outcomes...

Leveraging the potential of Patient Reported Outcome (PRO) data to...

Gastrointestinal Tract Diseases Research: Moving Towards Patient-Centered Clinical Trials

Turning experience into evidence: PROs in IBD clinical research

BYOD on the rise

Strategies to promote BYOD adoption by clinical study sites

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events

The critical importance of Patient Reported Outcomes (PROs) for Emerging Biopharma Companies – Webinar

July 9 • 11-12AM EDT / 4-5PM GMT / 5-6PM CET

In today’s competitive landscape, biotech and emerging biopharma companies (EBPs) must demonstrate the value of their innovations early and convincingly....